Electra Therapeutics is a clinical-stage biotechnology company developing Signal Regulatory Protein (SIRP)-directed therapies for immune-mediated diseases and cancer. The company’s approach harnesses the biology of SIRP to selectively deplete activated, disease-driving immune cells. Its lead product candidate, ELA026, is in clinical development for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), with plans to expand into other indications. The company is also advancing two additional programs toward the clinic. Electra Therapeutics was built from discovery stage into the clinic by Star Therapeutics, where its leadership team previously held operational and strategic responsibilities.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage electra-therapeutics.com
Sector Healthcare IR page —
Tags
signal regulatory proteins, immune-mediated diseases, hemophagocytic lymphohistiocytosis, antibody therapeutics, clinical-stage, precision medicine, ELA026
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 2
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026
Assets 410.822M
Net profit -23.928M

Figure Q3 2026
Share price 11.25
P/BV 1.8

Filed figures

Figure Dec 2025
Balance sheet detail
Lease liabilities (USD) 2.09M
Cash and deposits (USD) 33M
Right-of-use assets (USD) 2.11M
Reported Nov 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Ipsoprubart Advancing in Global Registrational Program as Potential First Treatment for sHLH Broadly; Enrollment Completion Expected in Second Half of 2027

Ipsoprubart Therapeutic Expansion Underway in Phase 1 Trial for T/NK Cell Malignancies, with Initial Data Expected in the Second Half of 2027

ELA822 Healthy Volunteer Data Expected in the First Half of 2027, with Patient Trial Initiation Planned for Mid-2027

Completed $350 Million IPO to Fund Advancement of SIRP-Targeting Portfolio

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2026 -- Electra Therapeutics, Inc. (Nasdaq: ETRA), a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today reported financial results for the third quarter ended September 30, 2026 and provided an overview of its portfolio and recent business highlights.

“Our recent IPO positions Electra to build on our first-mover advantage in SIRP-targeted precision immune cell depletion,” said Kathy Dong, PharmD, MBA, President and Chief Executive Officer of Electra Therapeutics.

Amendment and Restatement of Certificate of Incorporation On September 21, 2026, in connection with the closing of the initial public offering (the “IPO”) of shares of common stock of Electra Therapeutics, Inc. (the “Company”) on September 21, 2026, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware. The Company’s board of directors (the “Board”) and stockholders previously approved the Restated Certificate to be effective upon the closing of the IPO. Amendment and Restatement of Bylaws Effective as of September 21, 2026, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO. The Board and stockholders previously approved the Restated Bylaws to be effective upon the closing of the IPO. Please see the description of the Restated Certificate and Restated Bylaws in the section titled “Description of Capital Stock” in the final prospectus the Company filed with the U.S.

Second clinical-stage asset generated from the company’s proprietary library of SIRP-targeted antibodies

SOUTH SAN FRANCISCO, CA, Sept. 10, 2026 – **Electra Therapeutics **, a clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced the initiation of a Phase 1 clinical trial of ELA822, a novel SIRPγ-specific monoclonal antibody, in healthy volunteers.

Signal regulatory proteins (SIRP) are a family of cell surface receptors whose expression is restricted to specific immune cell populations and increases upon activation, enabling selective depletion of disease-driving cells while preserving normal immune function. ELA822 is a fully human IgG1κ monoclonal antibody designed to selectively bind SIRPγ, with no binding to SIRPα or SIRPβ1. SIRPγ is expressed predominantly on T cells, and by engaging cells expressing high levels of SIRPγ, ELA822 is designed to deplete activated, pathogenic T cells while sparing naïve and regulatory T cells.

“We have built significant expertise at Electra in the biology of SIRP protein expression across activated immune cell populations and applying that biology to precision immune cell depletion,” said Graham Parry, Ph.D., Chief Scientific Officer of Electra Therapeutics. “Selective targeting of individual SIRP members has historically been challenging, and because SIRPγ is expressed only in primates, preclinical characterization of SIRPγ-targeted therapies has been limited. Our discovery platform has produced antibodies with well-defined and differentiated binding characteristics, ranging from pan-SIRP engagement, as with our lead clinical candidate, ipsoprubart, to highly specific SIRPγ targeting, as with ELA822. We have also built humanized model systems to evaluate SIRPγ engagement. In those, ELA822 demonstrated selective depletion of activated T cells in vitro and activity in humanized mouse models of T cell-driven diseases in vivo_._”

In nonclinical models of giant cell arteritis and graft-versus-host disease, ELA822 reduced activated T cell infiltration and inflammatory cytokine expression and was associated with improvements in measures of disease activity and survival. ELA822 was also well-tolerated in non-human primate studies. Based on the preclinical data, Electra has advanced ELA822 into clinical development. The Phase 1 trial is a randomized, placebo-controlled, single-ascending-dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ELA822 in healthy volunteers.

“ELA822 is the second development candidate from our proprietary library of SIRP-targeted antibodies to advance into the clinic, extending our precision immune cell depletion approach to address unmet needs in chronic immune and inflammatory diseases,” said Kim-Hien Dao, D.O., Ph.D., Chief Medical Officer of Electra Therapeutics. “Many approaches to T cell-driven diseases broadly suppress or deplete immune cells, which can limit their use in chronic settings. By selectively targeting SIRPγ to deplete activated pathogenic T cells, we believe ELA822 may be well suited for a broad range of chronic T cell-mediated diseases where durable efficacy and long-term tolerability are important therapeutic objectives.”

About Electra Therapeutics

**Electra Therapeutics ** is a clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company’s novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression is restricted to specific immune cell populations and increases upon activation, to enable selective depletion of disease-driving cells while preserving normal immune function. The company’s lead product candidate, ipsoprubart (ELA026), is a novel pan-SIRP monoclonal antibody currently in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory syndrome for which there are no broadly approved therapies and survival has remained consistently poor over the past two decades. Ipsoprubart is also being evaluated in a clinical trial for T cell and natural killer cell malignancies. ELA822, the company’s second clinical-stage product candidate, is a novel SIRPγ-specific antibody being developed for a broad range of chronic T cell-mediated immune and inflammatory diseases. For more information, please visit **electra‑therapeutics.com ** and follow us on LinkedIn .

**Investors Contact:
**Monique Allaire, THRUST
**[email protected] **

Media Contact:
Sara Sutton, THRUST
**[email protected] **

< Return to news

Electra_Logo

230 E Grand Avenue, Suite S-100
South San Francisco, CA 94080
[email protected]

© 2026 Electra Therapeutics Inc.

Company’s first-in-class approach to targeting of signal regulatory proteins (SIRP) enables specific depletion of pathological immune cells

Financing enables lead product candidate, ELA026, to reach clinical proof of concept in the inflammatory disease sHLH, expansion of ELA026 into other indications, and advancement of two additional programs towards the clinic

Zip Code:

Get Information

×

No Contact Available

Site has not yet provided contact information. You may wish to check back again in the future.

×

Please complete the challenge

There is no contact information available for this site at this time. Please check back later.

×

Prompts

Electra Therapeutics, Inc. (ticker ETRA), listed in United States.